Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bausch + Lomb Corporation Common Shares
(NY:
BLCO
)
11.73
+0.18 (+1.56%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bausch + Lomb Corporation Common Shares
< Previous
1
2
3
4
5
Next >
3 Value Stocks in Hot Water
June 10, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...
Via
StockStory
3 Stocks Under $50 with Questionable Fundamentals
June 09, 2025
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...
Via
StockStory
3 of Wall Street’s Favorite Stocks with Mounting Challenges
June 05, 2025
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
1 Safe-and-Steady Stock for Long-Term Investors and 2 to Question
June 03, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via
StockStory
Earnings Scheduled For April 30, 2025
April 30, 2025
Via
Benzinga
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
May 29, 2025
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Via
Benzinga
Exposures
Product Safety
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know
May 27, 2025
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports,...
Via
StockStory
Topics
Government
Stocks
World Trade
Exposures
Political
Tariff
US Equities
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
May 16, 2025
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.
Via
Benzinga
BLCO Q1 Earnings Call: Misses on Profit, Highlights Product Innovation and Tariff Uncertainty
May 14, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) fell short of the market’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year...
Via
StockStory
Topics
World Trade
Exposures
Tariff
3 Profitable Stocks Walking a Fine Line
May 08, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
Topics
Economy
Supply Chain
Exposures
Coal
Supply Chain
Why Bausch + Lomb (BLCO) Shares Are Falling Today
April 30, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's...
Via
StockStory
Topics
Initial Public Offering
Exposures
Securities Market
Wednesday's session: gap up and gap down stocks
April 30, 2025
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
April 30, 2025
Via
Benzinga
Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%
April 30, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue...
Via
StockStory
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
April 29, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know.
Via
StockStory
Topics
World Trade
Exposures
Tariff
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 28, 2025
Via
Benzinga
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
April 18, 2025
Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move.
Via
StockStory
Topics
Bankruptcy
Exposures
Financial
Legal
3 of Wall Street’s Favorite Stocks in the Doghouse
April 16, 2025
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...
Via
StockStory
Topics
Firearms
Exposures
Firearms
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
April 07, 2025
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.
Via
StockStory
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
April 04, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and...
Via
StockStory
Why Bausch + Lomb (BLCO) Shares Are Plunging Today
March 28, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Exposures
Artificial Intelligence
Securities Market
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
March 28, 2025
Via
Benzinga
Why Bausch + Lomb (BLCO) Stock Is Nosediving
March 27, 2025
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was...
Via
StockStory
Topics
Artificial Intelligence
Initial Public Offering
Exposures
Artificial Intelligence
Securities Market
3 Healthcare Stocks in the Doghouse
March 25, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
March 11, 2025
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Via
StockStory
3 Stocks Under $50 Walking a Fine Line
February 28, 2025
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...
Via
StockStory
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
February 19, 2025
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Via
Stocktwits
Topics
Earnings
Exposures
Financial
Globus Medical (GMED) Q4 Earnings: What To Expect
February 19, 2025
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect.
Via
StockStory
Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
February 19, 2025
Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.
Via
StockStory
Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
February 19, 2025
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year...
Via
StockStory
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.